BCI
SMMT icon

Brinker Capital Investments’s Summit Therapeutics SMMT Stock Holding History

Brinker Capital Investments’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,278
Closed -$419K – 2190
2025
Q3 		$419K Sell
20,278
-32,686
-62% -$793K ﹤0.01% 1614
2025
Q2 		$1.13M Buy
52,964
+29,994
+131% +$684K 0.01% 1131
2025
Q1 		$443K Buy
22,970
+12,141
+112% +$244K ﹤0.01% 1470
2024
Q4 		$193K Buy
+10,829
New +$210K ﹤0.01% 1758

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
PCMH
Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Brinker Capital Investments's SMMT Position: Q4 2025 in Review

Brinker Capital Investments sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 20,278 shares — an estimated $419K sold.

Brinker Capital Investments first reported a position in SMMT in Q4 2024 and held it in 4 quarters. The position peaked at $1.13M in Q2 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

  • Brinker Capital Investments reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brinker Capital Investments sold 20,278 Summit Therapeutics shares in Q4 2025, an estimated $419K.
  • Brinker Capital Investments first reported a position in Summit Therapeutics in Q4 2024 and held it in 4 quarters.
  • Brinker Capital Investments's Summit Therapeutics position peaked at $1.13M in Q2 2025.
  • 206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on Brinker Capital Investments's 13F filing for Q4 2025, filed 12 Feb 2026.